| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $145,526 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Lynx1 Capital Management LP | 10 percent owner | 3 | $145,526 | 0 | $0 | $145,526 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It …
Over the last 12 months, insiders at TScan Therapeutics, Inc. have bought $145,526 and sold $0 worth of TScan Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TScan Therapeutics, Inc. have bought $1.35M and sold $508,034 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lynx1 Capital Management LP (10 percent owner) — $145,526.
The last purchase of 6,232 shares for transaction amount of $5,602 was made by Lynx1 Capital Management LP (10 percent owner) on 2025‑12‑23.
| 2025-12-23 | Lynx1 Capital Management LP | 10 percent owner | 6,232 0.011% | $0.90 | $5,602 | +8.84% | ||
| 2025-12-22 | Lynx1 Capital Management LP | 10 percent owner | 75,500 0.1329% | $0.90 | $67,950 | +9.72% | ||
| 2025-12-19 | Lynx1 Capital Management LP | 10 percent owner | 80,069 0.1416% | $0.90 | $71,974 | +10.04% | ||
| 2025-05-20 | Lynx1 Capital Management LP | 10 percent owner | 1.2M 2.103% | $1.20 | $1.44M | +0.83% | ||
| 2025-05-19 | Lynx1 Capital Management LP | 10 percent owner | 1.39M 2.3749% | $1.20 | $1.67M | -1.61% | ||
| 2024-12-13 | Lynx1 Capital Management LP | 10 percent owner | 100,000 0.1862% | $2.90 | $290,140 | -37.89% | ||
| 2024-12-12 | Lynx1 Capital Management LP | 10 percent owner | 31,800 0.0595% | $3.01 | $95,629 | -41.39% | ||
| 2024-11-15 | Lynx1 Capital Management LP | 10 percent owner | 947 0.0016% | $4.34 | $4,114 | -58.73% | ||
| 2024-09-23 | Klencke Barbara | director | 5,000 0.0104% | $5.29 | $26,450 | -64.13% | ||
| 2024-08-26 | Klencke Barbara | director | 5,000 0.0109% | $5.53 | $27,650 | -64.20% | ||
| 2024-08-23 | Sale | ZDRAVESKI ZORAN | See Remarks | 164,686 0.374% | $5.78 | $952,116 | -63.84% | |
| 2024-08-23 | Klencke Barbara | director | 5,000 0.0112% | $5.69 | $28,450 | -63.84% | ||
| 2023-12-19 | BARBERICH TIMOTHY J | director | 317 0.0006% | $4.97 | $1,575 | +20.82% | ||
| 2023-12-18 | BARBERICH TIMOTHY J | director | 28,830 0.0553% | $4.89 | $140,881 | +28.42% | ||
| 2023-12-14 | Klencke Barbara | director | 5,000 0.01% | $5.08 | $25,400 | +18.40% | ||
| 2023-06-02 | BARBERICH TIMOTHY J | director | 37,880 0.0391% | $2.63 | $99,564 | +77.58% | ||
| 2023-05-31 | Sale | Lynx1 Capital Management LP | 10 percent owner | 25,400 0.0251% | $2.52 | $63,953 | +116.52% | |
| 2022-12-28 | Silver Brian M. | Chief Financial Officer | 3,158 0.0019% | $1.56 | $4,941 | +66.11% | ||
| 2022-12-27 | Silver Brian M. | Chief Financial Officer | 2,842 0.0017% | $1.50 | $4,276 | +74.70% | ||
| 2022-05-18 | SOUTHWELL DAVID P | Chief Executive Officer | 25,000 0.0353% | $3.59 | $89,821 | -21.23% |
| Lynx1 Capital Management LP | 10 percent owner | 8019148 12.6281% | $1.52M | 8 | 1 | <0.0001% |
| BAKER BROS. ADVISORS LP | 2528583 3.9819% | $477,902.19 | 3 | 0 | +7.69% | |
| Baker Brothers Life Sciences LP | 2528583 3.9819% | $477,902.19 | 1 | 0 | +40.95% | |
| Westphal Christoph H | 10 percent owner | 1278838 2.0138% | $241,700.38 | 1 | 0 | <0.0001% |
| SOUTHWELL DAVID P | Chief Executive Officer | 171569 0.2702% | $32,426.54 | 2 | 0 | <0.0001% |
| BARBERICH TIMOTHY J | director | 67027 0.1055% | $12,668.10 | 3 | 0 | +42.27% |
| MacBeath Gavin | Chief Scientific Officer | 49767 0.0784% | $9,405.96 | 2 | 0 | <0.0001% |
| Klencke Barbara | director | 45000 0.0709% | $8,505.00 | 4 | 0 | <0.0001% |
| Silver Brian M. | Chief Financial Officer | 32885 0.0518% | $6,215.27 | 6 | 0 | <0.0001% |
| ZDRAVESKI ZORAN | See Remarks | 4716 0.0074% | $891.32 | 1 | 1 | <0.0001% |
| Desmarais William | Chief Business Officer | 2500 0.0039% | $472.50 | 1 | 0 | <0.0001% |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
$95,567,744 | 39 | -17.01% | $10.94M | |
TScan Therapeutics, Inc. (TCRX) | $30,257,839 | 29 | -15.72% | $12M |
$76,600 | 22 | -38.58% | $10.49M |
| Increased Positions | 27 | +27.84% | 3M | +8.84% |
| Decreased Positions | 41 | -42.27% | 6M | -17.51% |
| New Positions | 10 | New | 605,580 | New |
| Sold Out Positions | 20 | Sold Out | 3M | Sold Out |
| Total Postitions | 83 | -14.43% | 31M | -8.67% |
| Lynx1 Capital Management Lp | $8,014.00 | 15.11% | 7.86M | 0 | 0% | 2025-09-30 |
| Bvf Inc/Il | $5,331.00 | 10.05% | 5.23M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $2,840.00 | 5.36% | 2.78M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $2,430.00 | 4.58% | 2.38M | -183,760 | -7.16% | 2025-09-30 |
| Vanguard Group Inc | $2,364.00 | 4.46% | 2.32M | +168,540 | +7.84% | 2025-09-30 |
| Propel Bio Management, Llc | $1,971.00 | 3.72% | 1.93M | -154,835 | -7.42% | 2025-09-30 |
| Aberdeen Group Plc | $1,382.00 | 2.61% | 1.35M | +463,372 | +51.98% | 2025-09-30 |
| Deer Management Co. Llc | $1,270.00 | 2.4% | 1.25M | 0 | 0% | 2025-09-30 |
| Simplify Asset Management Inc. | $923.00 | 1.74% | 904,972 | -141,944 | -13.56% | 2025-09-30 |
| Morgan Stanley | $864.00 | 1.63% | 847,537 | -5,809 | -0.68% | 2025-09-30 |